Activated protein C in septic shock: a propensity-matched analysis. Critical Care 2011, 15:R89
Sadaka, F., et al.
http://ccforum.com/content/15/2/R89
The use of human recombinant activated protein C (rhAPC) for the treatment of severe sepsis remains controversial despite multiple reported trials. The efficacy of rhAPC remains a matter of dispute. We hypothesized that patients with septic shock who were treated with rhAPC had an improved in-hospital mortality compared to patients with septic shock with similar acuity who did not receive rhAPC.
No comments:
Post a Comment